Form 4: TransMedics Group CEO Waleed Hassanein Executes Stock Option and Sells Shares

CEO Waleed Hassanein exercised stock options and sold shares of TransMedics Group, Inc. under a pre-arranged trading plan.

Summary

• Waleed H. Hassanein, CEO of TransMedics Group, Inc., executed a transaction involving the company's stock on April 10, 2024.
• Hassanein exercised stock options to acquire 12,000 shares of common stock at a price of $13.28 per share.
• Simultaneously, Hassanein sold 12,000 shares of common stock at a weighted average price of $95.09 per share, with individual sales ranging from $95.00 to $95.54.
• These transactions were conducted under a Rule 10b5-1 trading plan established on September 6, 2023.
• Following these transactions, Hassanein directly owns 74,087 shares of common stock and indirectly owns 469,359 shares through the Waleed H. Hassanein Revocable Trust.
• He also directly owns options to purchase 238,000 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the executive's confidence in the company.

Positives

• The transactions were executed under a pre-existing 10b5-1 trading plan, which can reassure investors that the sales were not based on insider information.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially leading to short-term price fluctuations.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are usually not a cause for concern.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.

Key Dates